Functional characterization of large conductance calcium-activated K+ channel openers in bladder and vascular smooth muscle.
Calcium activated K(+) channels (K(Ca) channels) are found in a variety of smooth muscle tissues, the most characterized of which are the large conductance K(Ca) channels (BK(Ca) or maxi-K(+) channels). Recent medicinal chemistry efforts have identified novel BK(Ca) openers including 2-amino-5-(2-fluoro-phenyl)-4-methyl-1H-pyrrole-3-carbonitrile (NS-8), BMS-204352 and its analog 3-(5-chloro-2-hydroxy-phenyl)-3-hydroxy-6-trifluoromethyl-1,3-dihydro-indol-2-one (compound 1), and 5,7-dichloro-4-(5-chloro-2-hydroxy-phenyl)-3-hydroxy-1H-quinolin-2-one (compound 2). Although these compounds are effective BK(Ca) openers as shown by electrophysiological methods, little is known about their effects on smooth muscle contractility. In this study, the responsiveness of structurally diverse BK(Ca) openers-NS-8, compounds 1 and 2 and the well characterized nonselective NS-1619-was assessed using segments of endothelium denuded rat aorta, rat and guinea pig detrusor precontracted with extracellular K(+), and Landrace pig detrusor stimulated by electrical field. In all preparations, the compounds tested inhibited or completely abolished contractions with similar potencies (-logIC(50) values: 3.8 to 5.1). In rat aorta, in the presence of 80 mM K(+), the compounds significantly shifted the concentration-response curve to the right compared with those obtained in 30 mM K(+). These data are consistent with K(+) channel (BK(Ca) channel) activation as the underlying mechanism of relaxation by compounds that share the electrophysiological property of BK(Ca) current activation. The similar potencies at detrusor and vascular smooth muscle suggest that the achievement of smooth muscle selectivity in vitro with the representative compounds examined in this study may prove to be a challenge when targeting BK(Ca) channels for smooth muscle indications such as overactive bladder.
Malysz
John
J
Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064, USA. john.malysz@abbott.com
Buckner
Steven A
SA
Daza
Anthony V
AV
Milicic
Ivan
I
Perez-Medrano
Arturo
A
Gopalakrishnan
Murali
M
D000818:Animals; D001562:Benzimidazoles / Q000494:pharmacology*; D004558:Electric Stimulation; D006168:Guinea Pigs; D007211:Indoles / Q000494:pharmacology*; D009126:Muscle Relaxation / Q000187:drug effects*; D009130:Muscle, Smooth / Q000187:drug effects*; D009131:Muscle, Smooth, Vascular / Q000187:drug effects*; D024681:Potassium Channels, Calcium-Activated / Q000187:drug effects*; D011758:Pyrroles / Q000494:pharmacology*; D051381:Rats; D001743:Urinary Bladder / Q000187:drug effects*
C480898:2-amino-3-cyano-5-(2-fluorophenyl)-4-methylpyrrole; C424388:BMS204352; D001562:Benzimidazoles; D007211:Indoles; D024681:Potassium Channels, Calcium-Activated; D011758:Pyrroles; C086491:NS 1619